Imunon (NASDAQ:IMNN) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Imunon (NASDAQ:IMNN) in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a $29.00 target price on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Imunon in a research report on Thursday, December 19th.

Imunon Stock Performance

Shares of NASDAQ:IMNN opened at $0.81 on Thursday. The firm has a market cap of $11.75 million, a price-to-earnings ratio of -0.43 and a beta of 2.03. The business has a 50-day simple moving average of $0.89 and a two-hundred day simple moving average of $0.95. Imunon has a fifty-two week low of $0.64 and a fifty-two week high of $3.65.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC grew its holdings in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 139,505 shares of the company’s stock after purchasing an additional 13,570 shares during the quarter. Geode Capital Management LLC owned approximately 0.96% of Imunon worth $133,000 as of its most recent filing with the Securities & Exchange Commission. 4.47% of the stock is owned by institutional investors and hedge funds.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.